Sertraline
| Evidence Level: L5 | Predicted Indications: 7 |
Table of Contents
Sertraline: Histrionic personality disorder (disease)
One-Sentence Summary
Sertraline is an SSRI antidepressant that is registered and marketed in Australia. The TxGNN model predicts it may be relevant to histrionic personality disorder (disease), but no clinical trials and no publications currently support this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Histrionic personality disorder (disease) |
| TxGNN Prediction Score | 0.9993 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data are not available for the data compiled for this report. Sertraline is an SSRI, a class that increases serotonin signalling, and this is the only mechanistic context available.
A possible, but speculative, link is serotonergic modulation of affective lability and impulsivity, which can feature in histrionic personality disorder. No data support this link. The same score of 0.9993 is shared by several other personality disorder predictions, which suggests the score may reflect a shared pattern in the model’s neighbourhood rather than a signal specific to this disease. The prediction should be treated as hypothesis-generating only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 14400X | Zoloft | Tablet 50 mg (as hydrochloride) | Not specified in the data compiled |
Safety Considerations
- Drug Interactions: 100 interactions were identified in the interaction query. Major-level interactions among those listed include bupropion, lorcaserin, diethylpropion, dolasetron, eliglustat, palonosetron and phentermine. Moderate-level interactions include famotidine, loperamide, morphine, acetylsalicylic acid, clarithromycin, and the sulfonylureas chlorpropamide and glimepiride, among others.
Please refer to the TGA-approved Product Information (PI) for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score alone. There are no clinical trials or publications for histrionic personality disorder, and the mechanistic link is speculative, so the evidence level is L5.
To proceed, the following is needed:
- Any clinical or published evidence that directly studies sertraline in histrionic personality disorder
- Detailed mechanism of action data
- TGA Product Information warnings and contraindications for a safety review
- A clear case for the clinical need and the target population before further evaluation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.